Naser Aslanabadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naser Aslanabadi has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Taher Entezari-Maleki
Department of clinical pharmacy Faculty of pharmacy Tabriz University of Medical Sciences Tabriz Iran
4 shared publications - Samad Ghaffari
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications - Ahmad Separham
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Elnaz Khani
Department of clinical pharmacy Faculty of pharmacy Tabriz University of Medical Sciences Tabriz Iran
2 shared publications Sajad Khiali
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publicationsSina Mashayekhi
Department of Cardiology, Cardiovascular Research Center Tabriz University of Medical Sciences Tabriz Iran
2 shared publications
Latest Publications
- Open Access
- 20 December 2025
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 18 (2) , 74-81
SGLT2 Inhibitors’ Effects on Biomarkers of Myocardial Injury: A Systematic Review
There is a lack of clinical data regarding sodium-glucose cotransporter-2 (SGLT2) inhibitors’ effects on myocardial injury, a common clinical condition that deteriorates patient prognosis. Hence, this systematic review aims to investigate the effects of SGLT2 inhibitors on myocardial injury, using the cardiac injury biomarkers, particularly high‐sensitivity cardiac troponin (hs-cTn). We performed a literature review on Embase, MEDLINE (PubMed), and the Cochrane Library, up to May 27, 2025. All potentially relevant randomized clinical trials (RCTs) assessing the effects of SGLT2 inhibitors on myocardial injury in individuals with diabetes or cardiovascular diseases were identified. The outcome measures were the most relevant cardiac injury biomarkers, including hs-cTnT and hs-cTnI, creatine kinase (CK)-MB, heart-type fatty acid-binding protein (H-FABP), myoglobin, lactate dehydrogenase (LDH), ischemia-modified albumin, and glycogen phosphorylase BB. In total, 1770 articles were identified through the literature search. After eliminating duplicates and screening articles, 10 studies involving 10440 participants were included. Of them, 6 studies evaluated hs-cTnT and 4 studies evaluated hs-cTnI. Among individuals with type 2 diabetes mellitus (T2DM), four of six trials showed significant attenuation in hs-cTn rise with SGLT2 inhibitors. In contrast, studies on HFrEF populations reported no significant change in hs-cTn levels. One study, including patients with acute myocardial infarction, also did not demonstrate a significant effect on hs-cTnI. The outcomes of this systematic review may suggest the potential effects of SGLT2 inhibitors in reducing myocardial injury by lowering hs-cTn levels in T2DM individuals. However, more studies are recommended to provide robust evidence.
- 20 December 2025
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 18 (2) , 74-81
Open AccessSGLT2 Inhibitors’ Effects on Biomarkers of Myocardial Injury: A Systematic Review
There is a lack of clinical data regarding sodium-glucose cotransporter-2 (SGLT2) inhibitors’ effects on myocardial injury, a common clinical condition that deteriorates patient prognosis. Hence, this systematic review aims to investigate the effects of SGLT2 inhibitors on myocardial injury, using the cardiac injury biomarkers, particularly high‐sensitivity cardiac troponin (hs-cTn). We performed a literature review on Embase, MEDLINE (PubMed), and the Cochrane Library, up to May 27, 2025. All potentially relevant randomized clinical trials (RCTs) assessing the effects of SGLT2 inhibitors on myocardial injury in individuals with diabetes or cardiovascular diseases were identified. The outcome measures were the most relevant cardiac injury biomarkers, including hs-cTnT and hs-cTnI, creatine kinase (CK)-MB, heart-type fatty acid-binding protein (H-FABP), myoglobin, lactate dehydrogenase (LDH), ischemia-modified albumin, and glycogen phosphorylase BB. In total, 1770 articles were identified through the literature search. After eliminating duplicates and screening articles, 10 studies involving 10440 participants were included. Of them, 6 studies evaluated hs-cTnT and 4 studies evaluated hs-cTnI. Among individuals with type 2 diabetes mellitus (T2DM), four of six trials showed significant attenuation in hs-cTn rise with SGLT2 inhibitors. In contrast, studies on HFrEF populations reported no significant change in hs-cTn levels. One study, including patients with acute myocardial infarction, also did not demonstrate a significant effect on hs-cTnI. The outcomes of this systematic review may suggest the potential effects of SGLT2 inhibitors in reducing myocardial injury by lowering hs-cTn levels in T2DM individuals. However, more studies are recommended to provide robust evidence.
- Open Access
- 14 November 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (11) , e70046
A Comparison Between Culprit Versus Complete Revascularization in Diabetic Patients With Acute Myocardial Infarction
Introduction: The benefit of complete revascularization in diabetic patients with myocardial infarction remains unclear. this study aims to find the optimal strategy of total vascular repair for diabetic patients with acute myocardial infarction.Methods: In an analysis of a cohort, we assigned diabetic patients with myocardial infarction who were undergoing percutaneous coronary intervention (PCI) of the culprit lesion to receive either staged complete revascularization of nonculprit lesions or to receive no further revascularization in Madani Hospital (Tabriz, Iran). Functionally significant nonculprit lesions were identified either by angiography. The primary outcome was rates of readmission, cardiac deaths, nonfatal myocardial re‐infarction, and overall mortality at 1 year.Results: In our center, a total of 1186 patients underwent primary‐PCI treatment, among which 521 were diagnosed with diabetes. Ultimately, 393 patients were selected for inclusion in the study. Within this cohort, 271 individuals (68.9%) underwent repair of only the culprit vessels (group 1), while 122 individuals (31.1%) received a comprehensive staged restoration of the vessels (group 2). During this time, group 1 in comparison with group 2 experienced 204 (75.3%) versus 97 (79.5%) cases of readmission, 48 (17.7%) versus 8 (6.5%) instances of cardiac death, 22 (8.1%) versus 18 (14.7%) occurrences of nonfatal myocardial re‐infarction. Notably, the incidence of cardiac death in group 2 were significantly lower than that in group 1 (p ≤ 0.05).Conclusions: For individuals diagnosed with diabetes, staged complete revascularization demonstrated a lower frequency of readmission, cardiac deaths, nonfatal myocardial reinfarction, and overall mortality, in contrast to revascularization that targeted only the culprit lesion.
- 14 November 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (11) , e70046
Open AccessA Comparison Between Culprit Versus Complete Revascularization in Diabetic Patients With Acute Myocardial Infarction
Introduction: The benefit of complete revascularization in diabetic patients with myocardial infarction remains unclear. this study aims to find the optimal strategy of total vascular repair for diabetic patients with acute myocardial infarction.Methods: In an analysis of a cohort, we assigned diabetic patients with myocardial infarction who were undergoing percutaneous coronary intervention (PCI) of the culprit lesion to receive either staged complete revascularization of nonculprit lesions or to receive no further revascularization in Madani Hospital (Tabriz, Iran). Functionally significant nonculprit lesions were identified either by angiography. The primary outcome was rates of readmission, cardiac deaths, nonfatal myocardial re‐infarction, and overall mortality at 1 year.Results: In our center, a total of 1186 patients underwent primary‐PCI treatment, among which 521 were diagnosed with diabetes. Ultimately, 393 patients were selected for inclusion in the study. Within this cohort, 271 individuals (68.9%) underwent repair of only the culprit vessels (group 1), while 122 individuals (31.1%) received a comprehensive staged restoration of the vessels (group 2). During this time, group 1 in comparison with group 2 experienced 204 (75.3%) versus 97 (79.5%) cases of readmission, 48 (17.7%) versus 8 (6.5%) instances of cardiac death, 22 (8.1%) versus 18 (14.7%) occurrences of nonfatal myocardial re‐infarction. Notably, the incidence of cardiac death in group 2 were significantly lower than that in group 1 (p ≤ 0.05).Conclusions: For individuals diagnosed with diabetes, staged complete revascularization demonstrated a lower frequency of readmission, cardiac deaths, nonfatal myocardial reinfarction, and overall mortality, in contrast to revascularization that targeted only the culprit lesion.
- Open Access
- 2 July 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (4) , e1228
Effectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial
Contrast‐induced nephropathy (CIN) is a serious complication that occurs subsequent to the administration of contrast media for therapeutic angiographic interventions. As of present, no effective therapy exists to prevent its occurrence. This single‐center double‐blind randomized controlled trial aimed to evaluate the effect of edaravone, an antioxidant, in a group of high‐risk patients undergoing coronary angiography. Ninety eligible patients with chronic kidney disease Stages 3–4 were randomly assigned to either the control group (n = 45) or the intervention group (n = 45). In the intervention group, one dosage of edaravone (60 mg) in 1 L of normal saline was infused via a peripheral vein 1 h prior to femoral artery‐directed coronary angiography. Patients in the control group received an equal amount of infusion in their last hour before angiography. Both groups received intravenous hydration with 0.9% sodium 1 mL/kg/h starting 12 h before and continuing for 24 h after angiography. The primary outcome measure was the onset of CIN, defined as a 25% increase in serum creatinine levels 120 h after administration of contrast media. The occurrence of CIN was observed in 5.5% (n = 5) of the studied population: 2.2% of patients in the intervention group (n = 1) and 8.9% of controls (n = 4). However, this difference was not statistically significant. Administration of a single dosage of edaravone 1 h prior to infusion of contrast media led to a reduction in the incidence of CIN. Further investigations, employing larger sample sizes, are warranted to gain a comprehensive understanding of its efficacy.
- 2 July 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (4) , e1228
Open AccessEffectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial
Contrast‐induced nephropathy (CIN) is a serious complication that occurs subsequent to the administration of contrast media for therapeutic angiographic interventions. As of present, no effective therapy exists to prevent its occurrence. This single‐center double‐blind randomized controlled trial aimed to evaluate the effect of edaravone, an antioxidant, in a group of high‐risk patients undergoing coronary angiography. Ninety eligible patients with chronic kidney disease Stages 3–4 were randomly assigned to either the control group (n = 45) or the intervention group (n = 45). In the intervention group, one dosage of edaravone (60 mg) in 1 L of normal saline was infused via a peripheral vein 1 h prior to femoral artery‐directed coronary angiography. Patients in the control group received an equal amount of infusion in their last hour before angiography. Both groups received intravenous hydration with 0.9% sodium 1 mL/kg/h starting 12 h before and continuing for 24 h after angiography. The primary outcome measure was the onset of CIN, defined as a 25% increase in serum creatinine levels 120 h after administration of contrast media. The occurrence of CIN was observed in 5.5% (n = 5) of the studied population: 2.2% of patients in the intervention group (n = 1) and 8.9% of controls (n = 4). However, this difference was not statistically significant. Administration of a single dosage of edaravone 1 h prior to infusion of contrast media led to a reduction in the incidence of CIN. Further investigations, employing larger sample sizes, are warranted to gain a comprehensive understanding of its efficacy.
- 1 June 2024
- Published by Apex Publishing in Journal of Advances in Medical and Biomedical Research
- Vol. 32 (152) , 209-218
Assessing ABO Blood Group Relation with Collateral Coronary Circulation Development Quality
- 1 June 2024
- Published by Apex Publishing in Journal of Advances in Medical and Biomedical Research
- Vol. 32 (152) , 209-218
Assessing ABO Blood Group Relation with Collateral Coronary Circulation Development Quality
- 24 September 2023
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 30 (1) , 129-134
Effects of Allopurinol in the Prevention of Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial
Background: Periprocedural myocardial injury (PMI) after percutaneous coronary intervention (PCI) is a substantial health issue with a high mortality rate. Inflammation and oxidative stress are major contributing factors to PMI. Allopurinol inhibits xanthine oxidase (XO)-induced oxidative stress and has potential cardiovascular benefits. Methods: This randomized clinical trial evaluated 110 patients admitted to elective PCI. Patients were assigned to receive either a 1200 mg loading dose of allopurinol 2 hours before the procedure (n = 55) or the standard pretreatment (n = 55). The creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured in both groups at the baseline, 8, and 24 hours after PCI. Results: There were no significant differences in the CK-MB levels at baseline (P = 0.71), 8 (P = 0.26), and 24 hours (P = 0.88) after PCI between the two groups. No significant changes in the cTnI levels at baseline (P = 0.26), 8 (P = 0.80), and 24 hours (P = 0.89) after the PCI were also noted. The mean difference for CK-MB and cTnI changes was not different between the two groups. Conclusion: Our study revealed that allopurinol did not reduce cardiac-specific enzymes. Further studies are required to evaluate the impact of allopurinol on preventing PCI-related myocardial injury.
- 24 September 2023
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 30 (1) , 129-134
Effects of Allopurinol in the Prevention of Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial
Background: Periprocedural myocardial injury (PMI) after percutaneous coronary intervention (PCI) is a substantial health issue with a high mortality rate. Inflammation and oxidative stress are major contributing factors to PMI. Allopurinol inhibits xanthine oxidase (XO)-induced oxidative stress and has potential cardiovascular benefits. Methods: This randomized clinical trial evaluated 110 patients admitted to elective PCI. Patients were assigned to receive either a 1200 mg loading dose of allopurinol 2 hours before the procedure (n = 55) or the standard pretreatment (n = 55). The creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured in both groups at the baseline, 8, and 24 hours after PCI. Results: There were no significant differences in the CK-MB levels at baseline (P = 0.71), 8 (P = 0.26), and 24 hours (P = 0.88) after PCI between the two groups. No significant changes in the cTnI levels at baseline (P = 0.26), 8 (P = 0.80), and 24 hours (P = 0.89) after the PCI were also noted. The mean difference for CK-MB and cTnI changes was not different between the two groups. Conclusion: Our study revealed that allopurinol did not reduce cardiac-specific enzymes. Further studies are required to evaluate the impact of allopurinol on preventing PCI-related myocardial injury.
- Open Access
- 4 March 2022
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 29 (1) , 59-64
The impact of metformin on cardiac troponin-I and ST resolution in patients with ST elevation myocardial infarction undergoing thrombolytic therapy
Background: Thrombolytic therapy is a key in the management of ST elevated myocardial infarction (STEMI). Metformin implies a series of cardioprotective effects. We aimed to investigate how pretreatment with metformin could affect cardiac troponin I (cTnI) levels following reteplase therapy amid STEMI patients. Methods: A pilot randomized clinical trial was carried out in 84 patients with STEMI undergoing thrombolytic therapy with reteplase. The metformin group (n = 42) received a single dose of 1000 mg metformin orally before receiving reteplase, while the control group (n = 42) received only reteplase. The serum level of cTnI was measured at baseline, 8, 16, 24, and 32 hours after the admission to assess myocardial damage. Results: No significant differences were observed in cTnI levels at baseline (p = 0.657), 8 (p = 0.93), 16 (p = 0.690), 24 (p = 0.217), and 32 (p = 0.517) hours after STEMI diagnose between two groups. The mean differences were also not significant for changes of cTnI at baseline and other time frames. Conclusion: The results of the present study indicated that early use of 1000 mg metformin prior to reteplase could not reduce the level of cTnI in STEMI patients.
- 4 March 2022
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 29 (1) , 59-64
Open AccessThe impact of metformin on cardiac troponin-I and ST resolution in patients with ST elevation myocardial infarction undergoing thrombolytic therapy
Background: Thrombolytic therapy is a key in the management of ST elevated myocardial infarction (STEMI). Metformin implies a series of cardioprotective effects. We aimed to investigate how pretreatment with metformin could affect cardiac troponin I (cTnI) levels following reteplase therapy amid STEMI patients. Methods: A pilot randomized clinical trial was carried out in 84 patients with STEMI undergoing thrombolytic therapy with reteplase. The metformin group (n = 42) received a single dose of 1000 mg metformin orally before receiving reteplase, while the control group (n = 42) received only reteplase. The serum level of cTnI was measured at baseline, 8, 16, 24, and 32 hours after the admission to assess myocardial damage. Results: No significant differences were observed in cTnI levels at baseline (p = 0.657), 8 (p = 0.93), 16 (p = 0.690), 24 (p = 0.217), and 32 (p = 0.517) hours after STEMI diagnose between two groups. The mean differences were also not significant for changes of cTnI at baseline and other time frames. Conclusion: The results of the present study indicated that early use of 1000 mg metformin prior to reteplase could not reduce the level of cTnI in STEMI patients.
- 24 November 2021
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 28 (4) , 596-602
Colchicine for the Prevention of Myocardial Injury Following Elective PCI: A Randomized Clinical Trial
Purpose: Considering the potential benefits of colchicine in coronary artery diseases, we aimed to carry out the present study to assess the impact of colchicine in the prevention of myocardial injury following elective percutaneous coronary intervention (PCI). Methods: A randomized, single-blinded, clinical trial was carried out on 102 patients undergoing elective PCI. All patients received the standard treatment prior to performing PCI. Moreover, the intervention group received 1, 0.5, 0.5 mg colchicine 12 to 18 hours before, 30-60 min before, and 12 hours after PCI, respectively. Serum concentrations of cardiac troponin I (cTnI) were measured before, 8, and 24 hours after the procedure to assess myocardial damage during PCI. Results: There were no significant differences in cTnI levels at baseline (P = 0.839), 8 (P = 0.729), and 24 hours (P = 0.398) after PCI between the intervention and the control groups. Likewise, no significant differences were seen regarding the mean differences of cTnI at baseline and 8 hours (P =0.190), at baseline and 24 hours (P = 0.780), and 8 and 24 hours after PCI (P = 0.680) in both groups. Conclusion: The study did not support the potential benefit of colchicine in the prevention of myocardial injury following elective PCI. Conducting well-designed randomized clinical trials with adequate sample size is recommended.
- 24 November 2021
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 28 (4) , 596-602
Colchicine for the Prevention of Myocardial Injury Following Elective PCI: A Randomized Clinical Trial
Purpose: Considering the potential benefits of colchicine in coronary artery diseases, we aimed to carry out the present study to assess the impact of colchicine in the prevention of myocardial injury following elective percutaneous coronary intervention (PCI). Methods: A randomized, single-blinded, clinical trial was carried out on 102 patients undergoing elective PCI. All patients received the standard treatment prior to performing PCI. Moreover, the intervention group received 1, 0.5, 0.5 mg colchicine 12 to 18 hours before, 30-60 min before, and 12 hours after PCI, respectively. Serum concentrations of cardiac troponin I (cTnI) were measured before, 8, and 24 hours after the procedure to assess myocardial damage during PCI. Results: There were no significant differences in cTnI levels at baseline (P = 0.839), 8 (P = 0.729), and 24 hours (P = 0.398) after PCI between the intervention and the control groups. Likewise, no significant differences were seen regarding the mean differences of cTnI at baseline and 8 hours (P =0.190), at baseline and 24 hours (P = 0.780), and 8 and 24 hours after PCI (P = 0.680) in both groups. Conclusion: The study did not support the potential benefit of colchicine in the prevention of myocardial injury following elective PCI. Conducting well-designed randomized clinical trials with adequate sample size is recommended.
- Open Access
- 7 November 2019
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 11 (4) , 329
Reply to: Comment on "Association of mean platelet volume with echocardiograffiric findings in patients with severe rheumatic mitral stenosis"
- 7 November 2019
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 11 (4) , 329
Open AccessReply to: Comment on "Association of mean platelet volume with echocardiograffiric findings in patients with severe rheumatic mitral stenosis"
- Open Access
- 30 September 2016
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 8 (3) , 113-118
Effect of remote ischemic post-conditioning on oxidative stress in blood of STEMI patients treated with primary angioplasty
Effect of remote ischemic post-conditioning on oxidative stress in blood of STEMI patients treated with primary angioplasty
- 30 September 2016
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 8 (3) , 113-118
Open AccessEffect of remote ischemic post-conditioning on oxidative stress in blood of STEMI patients treated with primary angioplasty
Effect of remote ischemic post-conditioning on oxidative stress in blood of STEMI patients treated with primary angioplasty